DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

Mitotic cell division increases tumour mutation burden and copy number load, predictive markers of the clinical benefit of immunotherapy. Cell division correlates also with genomic demethylation involving methylation loss in late-replicating partial methylation domains. Here we find that immunomodulatory pathway genes are concentrated in these domains and transcriptionally repressed in demethylated tumours with CpG island promoter hypermethylation. Global methylation loss correlated with immune evasion signatures independently of mutation burden and aneuploidy. Methylome data of our cohort (n = 60) and a published cohort (n = 81) in lung cancer and a melanoma cohort (n = 40) consistently demonstrated that genomic methylation alterations counteract the contribution of high mutation burden and increase immunotherapeutic resistance. Higher predictive power was observed for methylation loss than mutation burden. We also found that genomic hypomethylation correlates with the immune escape signatures of aneuploid tumours. Hence, DNA methylation alterations implicate epigenetic modulation in precision immunotherapy. Demethylation of the genome is found in cancer. Here, the authors show that genomic demethylation entails changes in promoter methylation and gene expression associated with immune escape and suggest that the epigenetic alterations may be an important determinant of responses to immunotherapy.

[1]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[2]  David T. W. Jones,et al.  Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing , 2014, Nature.

[3]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[4]  C. Zahnow,et al.  Combining Epigenetic and Immunotherapy to Combat Cancer. , 2016, Cancer research.

[5]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[6]  Elizabeth M. Smigielski,et al.  dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..

[7]  Michael P. Snyder,et al.  Whole-Exome Enrichment with the Agilent SureSelect Human All Exon Platform. , 2015, Cold Spring Harbor protocols.

[8]  M. Ringnér,et al.  Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation , 2018, Nature Communications.

[9]  Hui Shen,et al.  DNA methylation loss in late-replicating domains is linked to mitotic cell division , 2018, Nature Genetics.

[10]  Rudolf Jaenisch,et al.  DNA hypomethylation leads to elevated mutation rates , 1998, Nature.

[11]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[12]  Ashton C. Berger,et al.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.

[13]  Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. , 2015, Cell.

[14]  Eric Talevich,et al.  CNVkit: Genome-Wide Copy Number Detection and Visualization from Targeted DNA Sequencing , 2016, PLoS Comput. Biol..

[15]  W. Lau,et al.  Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. , 2001, The American journal of pathology.

[16]  M. Beckmann,et al.  Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses , 2016 .

[17]  Angelika Amon,et al.  Chromosome Mis-segregation Generates Cell-Cycle-Arrested Cells with Complex Karyotypes that Are Eliminated by the Immune System. , 2017, Developmental cell.

[18]  G. Pfeifer.  Hydroxymethylated cytosine in development and disease , 2013, Epigenetics & Chromatin.

[19]  Lee E. Edsall,et al.  Human DNA methylomes at base resolution show widespread epigenomic differences , 2009, Nature.

[20]  J. Michael Cherry,et al.  The Encyclopedia of DNA elements (ENCODE): data portal update , 2017, Nucleic Acids Res..

[21]  S. Matsui,et al.  Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. , 2005, Cancer research.

[22]  P. Laird,et al.  Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina–associated domains , 2011, Nature Genetics.

[23]  M. Ellis,et al.  CDK4/6 inhibition triggers anti-tumor immunity , 2017, Nature.

[24]  Ruth L. Seal,et al.  A revised nomenclature for transcribed human endogenous retroviral loci , 2011, Mobile DNA.

[25]  C. Paweletz,et al.  CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. , 2017, Cancer discovery.

[26]  Winston Timp,et al.  Large hypomethylated blocks as a universal defining epigenetic alteration in human solid tumors , 2014, Genome Medicine.

[27]  John D Lambris,et al.  Complement in cancer: untangling an intricate relationship , 2017, Nature Reviews Immunology.

[28]  Colin N. Dewey,et al.  RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome , 2011, BMC Bioinformatics.

[29]  M. Fraga,et al.  Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. , 2006, Cancer research.

[30]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[31]  Tae Min Kim,et al.  Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers , 2017, Nature Communications.

[32]  Kentaro Yamashita,et al.  Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. , 2006, Cancer cell.

[33]  N. Friedman,et al.  Dynamic and static maintenance of epigenetic memory in pluripotent and somatic cells , 2014, Nature.

[34]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[35]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[36]  J. Wiemels,et al.  Genome-wide CpG island methylation and intergenic demethylation propensities vary among different tumor sites , 2015, Nucleic acids research.

[37]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[38]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[39]  C. Zahnow,et al.  Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer , 2017, Cell.

[40]  Nicolai J. Birkbak,et al.  Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade , 2016, Science.

[41]  Nadeem Riaz,et al.  Recurrent SERPINB3 and SERPINB4 Mutations in Patients that Respond to Anti-CTLA4 Immunotherapy , 2016, Nature Genetics.

[42]  A. Di Leonardo,et al.  DNA demethylation caused by 5-Aza-2′-deoxycytidine induces mitotic alterations and aneuploidy , 2016, Oncotarget.

[43]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[44]  Kimberly Walter,et al.  Quantitative comparison of DNA methylation assays for biomarker development and clinical applications , 2016, Nature Biotechnology.

[45]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[46]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[47]  C. Walsh,et al.  Cell Lineage Analysis in Human Brain Using Endogenous Retroelements , 2015, Neuron.

[48]  M. DePristo,et al.  The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. , 2010, Genome research.

[49]  Zlatko Trajanoski,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[50]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Method of the Year 2017: Organoids , 2018, Nature Methods.

[52]  S. Hirohashi,et al.  Correlation of DNA hypomethylation at pericentromeric heterochromatin regions of chromosomes 16 and 1 with histological features and chromosomal abnormalities of human breast carcinomas. , 2002, The American journal of pathology.

[53]  Hui Yang,et al.  Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.

[54]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[55]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[56]  E. King,et al.  Pan-cancer deconvolution of tumour composition using DNA methylation , 2018, Nature Communications.

[57]  Brian J. Stevenson,et al.  Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. , 2012, Genome research.

[58]  R. Jaenisch,et al.  Induction of Tumors in Mice by Genomic Hypomethylation , 2003, Science.

[59]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[60]  Christopher T. Saunders,et al.  Strelka2: fast and accurate calling of germline and somatic variants , 2018, Nature Methods.

[61]  Rafael A. Irizarry,et al.  Minfi: a flexible and comprehensive Bioconductor package for the analysis of Infinium DNA methylation microarrays , 2014, Bioinform..

[62]  Pau Farré,et al.  Additional annotation enhances potential for biologically-relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array , 2013, Epigenetics & Chromatin.

[63]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[64]  J. Issa,et al.  A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. , 2004, Nucleic acids research.

[65]  Christian B. Woods,et al.  Analysis of repetitive element DNA methylation by MethyLight , 2005, Nucleic acids research.

[66]  P. A. Futreal,et al.  Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance , 2017, Science Translational Medicine.

[67]  G. Getz,et al.  Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.

[68]  V. Verkhusha,et al.  Fast reversibly photoswitching red fluorescent proteins for live-cell RESOLFT nanoscopy , 2018, Nature Methods.

[69]  D. Karolchik,et al.  The UCSC Genome Browser database: 2016 update , 2015, bioRxiv.

[70]  David Haussler,et al.  ENCODE Data in the UCSC Genome Browser: year 5 update , 2012, Nucleic Acids Res..

[71]  Elisabeth Brambilla,et al.  Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. , 2018, The Lancet. Respiratory medicine.

[72]  M. Ehrlich,et al.  Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. , 1999, Cancer genetics and cytogenetics.

[73]  E. Rasmussen,et al.  The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. , 2018, Cell reports.

[74]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[75]  N. Tommerup,et al.  Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene , 1999, Nature.

[76]  R. Schreiber,et al.  The odds of immunotherapy success , 2015, Science.

[77]  Yuan Tian,et al.  ChAMP: updated methylation analysis pipeline for Illumina BeadChips , 2017, Bioinform..

[78]  Thomas Lengauer,et al.  A comprehensive analysis of 195 DNA methylomes reveals shared and cell-specific features of partially methylated domains , 2018, Genome Biology.